Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tristel PLC (TSTL.L)
GBp380.00
-2.50 (-0.65%)
GB LSE Healthcare Medical - Instruments & Supplies
Address
Lynx Business Park CB8 7NY
Newmarket, GB
Newmarket, GB
CEO
Matthew Giovanni Sassone
Website
tristel.com
IPO
2005-06-01
ISIN GB00B07RVT99
Also trades on
London Stock Exchange · TSTL.L (GBp)
Other OTC · TSNLF (USD)
Description
Tristel plc is a company specializing in the creation, production, and global distribution of products designed to prevent infections, serving both its home market in the UK and international clients. Its operations are structured around three core divisions: the decontamination of medical devices within hospital environments, the disinfection of hospital-based environmental surfaces, and an additional 'Other' category. The firm offers an extensive range of disinfection solutions for medical instruments under its Tristel brand. These solutions are applied across a wide spectrum of clinical areas, including airway management, cardiology, ear, nose and throat (ENT), endoscopy, gastrointestinal physiology, laboratory applications, ophthalmology, phlebotomy, reproductive health/IVF, general surface disinfection, ultrasound, urology, and women's health, alongside other specialized products. Tristel plc was established in 1993 and has its main office situated in Snailwell, United Kingdom.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp380.00
-2.50 (-0.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
144.4K
Beta
0.34
Float Shares
46.10M
Free Float %
96.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.68% | -0.65% | -2.42% | -4.38% | +4.79% | -8.38% | +6.84% | +6.99% | -37.30% | +240.00% | +635.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
380.00
DCF (Unlevered)
1,039.67
+173.6%
DCF (Levered)
1,475.71
+288.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
13.61
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+10.8% ★ Q4'25: +22.5% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+0.0% Q4'25: +28.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+18.1% Q4'25: +19.9% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+18.7% ★ Q4'25: +19.6% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+26.3% ★ Q4'25: +61.4% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.4% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.51× ★ Q4'25: 0.22× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 5 Rev. Ana. 4 EPS Ana. |
Jun 2027 5 Rev. Ana. 3 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 2 Rev. Ana. 1 EPS Ana. |
Jun 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.96M
est: 6.09M (-2.1%)
|
6.85M
est: 7.00M (-2.2%)
|
8.76M
est: 9.34M (-6.1%)
|
9.29M
est: 9.44M (-1.6%)
|
10.94M
est: 10.86M (+0.7%)
|
10.56M
est: 10.35M (+2.0%)
|
13.47M
est: 13.64M (-1.3%)
|
15.33M
est: 15.25M (+0.6%)
|
17.10M
est: 17.05M (+0.3%)
|
20.27M
est: 20.13M (+0.7%)
|
22.22M
est: 22.20M (+0.1%)
|
26.17M
est: 26.00M (+0.7%)
|
31.68M
est: 31.60M (+0.2%)
|
31.00M
est: 31.00M (0.0%)
|
31.12M
est: 28.40M (+9.6%)
|
36.01M
est: 36.00M (+0.0%)
|
41.93M
est: 41.90M (+0.1%)
|
46.46M
est: 46.50M (-0.1%)
|
51.19M
51.00M – 51.50M
+10.1% YoY
|
56.30M
55.77M – 57.58M
+10.0% YoY
|
61.81M
61.40M – 62.73M
+9.8% YoY
|
72.01M
71.54M – 73.09M
+16.5% YoY
|
80.70M
80.17M – 81.90M
+12.1% YoY
|
| EBITDA |
1.58M
est: 1.35M (+17.1%)
|
1.69M
est: 1.53M (+11.1%)
|
2.24M
est: 2.03M (+10.3%)
|
1.20M
est: 2.06M (-41.8%)
|
1.64M
est: 2.37M (-30.7%)
|
-702.0K
est: 2.25M (-131.1%)
|
2.71M
est: -896.0K (+402.5%)
|
3.40M
est: 3.11M (+9.4%)
|
3.55M
est: 3.81M (-7.0%)
|
5.19M
est: 4.23M (+22.8%)
|
5.48M
est: 4.93M (+11.2%)
|
6.17M
est: 5.77M (+6.9%)
|
9.30M
est: 7.02M (+32.5%)
|
6.70M
est: 6.88M (-2.6%)
|
4.46M
est: 9.59M (-53.5%)
|
7.90M
est: 8.00M (-1.2%)
|
10.01M
est: 8.92M (+12.2%)
|
11.48M
est: 9.90M (+15.9%)
|
10.90M
10.86M – 10.96M
+10.1% YoY
|
11.98M
11.87M – 12.26M
+10.0% YoY
|
13.16M
13.07M – 13.35M
+9.8% YoY
|
15.33M
15.23M – 15.56M
+16.5% YoY
|
17.18M
17.07M – 17.43M
+12.1% YoY
|
| EBIT |
1.28M
est: 878.6K (+45.2%)
|
1.29M
est: 990.5K (+30.4%)
|
1.74M
est: 1.32M (+32.1%)
|
536.0K
est: 1.33M (-59.8%)
|
591.0K
est: 1.54M (-61.5%)
|
-1.73M
est: 1.46M (-218.2%)
|
1.82M
est: -2.29M (+179.3%)
|
2.54M
est: 2.06M (+23.1%)
|
2.69M
est: 2.84M (-5.3%)
|
3.95M
est: 3.03M (+30.4%)
|
4.01M
est: 3.20M (+25.2%)
|
4.75M
est: 3.75M (+26.6%)
|
6.81M
est: 4.56M (+49.4%)
|
3.96M
est: 4.47M (-11.5%)
|
1.75M
est: 7.19M (-75.7%)
|
5.35M
est: 5.19M (+3.0%)
|
7.30M
est: 5.81M (+25.7%)
|
8.68M
est: 6.45M (+34.6%)
|
7.10M
7.07M – 7.14M
+10.1% YoY
|
7.80M
7.73M – 7.98M
+10.0% YoY
|
8.57M
8.51M – 8.70M
+9.8% YoY
|
9.98M
9.92M – 10.13M
+16.5% YoY
|
11.19M
11.11M – 11.35M
+12.1% YoY
|
| Net Income |
1.05M
est: 1.64M (-36.2%)
|
919.0K
est: 1.85M (-50.2%)
|
1.22M
est: 2.63M (-53.8%)
|
476.0K
est: 1.07M (-55.4%)
|
707.0K
est: 1.07M (-33.8%)
|
-1.26M
est: 291.4K (-533.8%)
|
1.30M
est: -1.66M (+178.2%)
|
2.22M
est: 1.47M (+50.3%)
|
2.10M
est: 2.48M (-15.2%)
|
3.42M
est: 2.48M (+37.9%)
|
3.27M
est: 3.92M (-16.5%)
|
4.03M
est: 4.92M (-18.1%)
|
5.10M
est: 5.88M (-13.3%)
|
3.66M
est: 4.73M (-22.7%)
|
987.0K
est: 6.17M (-84.0%)
|
4.46M
est: 4.59M (-2.9%)
|
6.49M
est: 5.71M (+13.7%)
|
6.64M
est: 7.72M (-14.0%)
|
8.08M
7.83M – 8.70M
+4.7% YoY
|
9.64M
8.84M – 10.75M
+19.2% YoY
|
11.48M
11.38M – 11.70M
+19.1% YoY
|
14.04M
13.92M – 14.32M
+22.4% YoY
|
16.04M
15.90M – 16.35M
+14.2% YoY
|
| SGA |
2.42M
est: 3.28M (-26.3%)
|
2.77M
est: 3.70M (-25.2%)
|
3.34M
est: 3.71M (-9.8%)
|
4.69M
est: 4.98M (-5.9%)
|
—
est: 5.73M (-100.0%)
|
5.52M
est: 5.36M (+3.0%)
|
6.69M
est: 7.29M (-8.3%)
|
7.24M
est: 7.60M (-4.7%)
|
8.24M
est: 8.14M (+1.2%)
|
10.34M
est: 10.51M (-1.6%)
|
10.97M
est: 11.95M (-8.2%)
|
13.58M
est: 13.99M (-2.9%)
|
15.45M
est: 17.00M (-9.1%)
|
16.38M
est: 19.15M (-14.5%)
|
17.55M
est: 22.09M (-20.6%)
|
20.22M
est: 19.39M (+4.3%)
|
23.12M
est: 23.04M (+0.3%)
|
25.32M
est: 25.57M (-1.0%)
|
28.15M
28.05M – 28.32M
+10.1% YoY
|
30.96M
30.67M – 31.67M
+10.0% YoY
|
33.99M
33.77M – 34.50M
+9.8% YoY
|
39.60M
39.34M – 40.19M
+16.5% YoY
|
44.38M
44.09M – 45.04M
+12.1% YoY
|
| EPS |
0.04
est: 0.03 (+21.4%)
|
0.03
est: 0.04 (-10.9%)
|
0.04
est: 0.05 (-29.6%)
|
0.01
est: 0.02 (-42.8%)
|
0.02
est: 0.02 (-20.3%)
|
-0.03
est: 0.01 (-621.5%)
|
0.03
est: 0.03 (-3.5%)
|
0.05
est: 0.04 (+27.7%)
|
0.05
est: 0.06 (-14.4%)
|
0.08
est: 0.07 (+9.4%)
|
0.08
est: 0.08 (-7.1%)
|
0.09
est: 0.10 (-11.3%)
|
0.11
est: 0.12 (-10.6%)
|
0.08
est: 0.10 (-20.6%)
|
0.02
est: 0.07 (-69.5%)
|
0.09
est: 0.10 (-1.8%)
|
0.14
est: 0.12 (+12.9%)
|
0.14
est: 0.16 (-11.5%)
|
0.17
0.16 – 0.18
+10.1% YoY
|
0.20
0.18 – 0.22
+17.3% YoY
|
0.24
0.24 – 0.24
+16.9% YoY
|
0.29
0.29 – 0.30
+22.4% YoY
|
0.33
0.33 – 0.34
+14.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
23.36M
OE per share TTM
0.49
Owner's Yield
12.79%
Maintenance CapEx ratio
17.54%
Maint CapEx / Avg PPE
21.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree UK Quality Dividend Growth UCITS ETF - GBP UGRW.L | 0.51% | 55.7K | 0.29% |
| 2 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.09% | 79.0K | 0.38% |
| 3 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.09% | 79.0K | 0.38% |
| 4 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.05% | 217.3K | 0.48% |
| 5 | WisdomTree International SmallCap Dividend Fund DLS | 0.05% | 483.8K | 0.58% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
37.2K
Shares Outstanding
47.99M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew G. Sassone | Chief Executive Officer & Director | 685.6K | male |
| Julija Shabanova | Executive Director | 367.2K | — |
| Aimee Scarbrow | Human Resources Director | — | — |
| Anna Katarzyna Wasyl | Chief Financial Officer & Director | — | female |
| Emily Davey | Global Marketing Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TSTL.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
